Skip to main content
Top
Published in: Infectious Diseases and Therapy 3/2016

Open Access 01-09-2016 | Review

Clostridium difficile Infection in Special High-Risk Populations

Authors: Alberto Cózar-Llistó, Antonio Ramos-Martinez, Javier Cobo

Published in: Infectious Diseases and Therapy | Issue 3/2016

Login to get access

Abstract

Antibiotic use continues to be the most important risk factor for the development of Clostridium difficile infection (CDI) through disruption of the indigenous microbiota of the colon. This factor, together with environmental contamination, makes hospital and other healthcare facilities the perfect breeding ground for the infection. Several groups of patients are exposed to the hospital environment and, at the same time, affected by conditions that can make CDI more prevalent, more severe or make it present a different clinical picture. The list of such conditions appears too extensive to be reviewed in a single article. Nevertheless, several groups, including the critically ill, oncological patients, solid organ and hematopoietic transplant recipients, patients with inflammatory bowel disease, patients with kidney disease and pregnant women, have generated more attention and have been studied in more detail. On the other hand, pediatric patients constitute a controversial group because the large number of asymptomatic carriers makes interpretation of clinical findings and diagnostic tests difficult, as is the development of an appropriate approach to treatment. We present an in-depth discussion of CDI in these high-risk populations and we also review the issue of CDI in pediatric patients.
Literature
1.
go back to reference McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerging Infect Dis. 2006;12:409–15.PubMedPubMedCentralCrossRef McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerging Infect Dis. 2006;12:409–15.PubMedPubMedCentralCrossRef
2.
go back to reference Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69:881–91.PubMedCrossRef Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69:881–91.PubMedCrossRef
3.
go back to reference Weber DJ, Anderson DJ, Sexton DJ, Rutala WA. Role of the environment in the transmission of Clostridium difficile in health care facilities. Am J Infect Control. 2013;41:S105–10.PubMedCrossRef Weber DJ, Anderson DJ, Sexton DJ, Rutala WA. Role of the environment in the transmission of Clostridium difficile in health care facilities. Am J Infect Control. 2013;41:S105–10.PubMedCrossRef
4.
go back to reference Longo DL, Leffler DA, Lamont JT. Clostridium difficile Infection. N Engl J Med. 2015;372:1539–48.CrossRef Longo DL, Leffler DA, Lamont JT. Clostridium difficile Infection. N Engl J Med. 2015;372:1539–48.CrossRef
5.
go back to reference Karanika S, Paudel S, Zervou FN, Grigoras C, Zacharioudakis IM, Mylonakis E. Prevalence and clinical outcomes of Clostridium difficile infection in the intensive care unit: a systematic review and meta-analysis. Open Forum Infect Dis. 2016; 3:ofv186–10. Karanika S, Paudel S, Zervou FN, Grigoras C, Zacharioudakis IM, Mylonakis E. Prevalence and clinical outcomes of Clostridium difficile infection in the intensive care unit: a systematic review and meta-analysis. Open Forum Infect Dis. 2016; 3:ofv186–10.
6.
go back to reference Alvarez-Lerma F, Palomar M, Villasboa A, et al. Epidemiological study of Clostridium difficile infection in critical patients admitted to the Intensive Care Unit. Med Intensiv. 2014;38:558–66.CrossRef Alvarez-Lerma F, Palomar M, Villasboa A, et al. Epidemiological study of Clostridium difficile infection in critical patients admitted to the Intensive Care Unit. Med Intensiv. 2014;38:558–66.CrossRef
7.
go back to reference Sabau L, Meybeck A, Gois J, et al. Clostridium difficile colitis acquired in the intensive care unit: outcome and prognostic factors. Infection. 2013;42:23–30.PubMedCrossRef Sabau L, Meybeck A, Gois J, et al. Clostridium difficile colitis acquired in the intensive care unit: outcome and prognostic factors. Infection. 2013;42:23–30.PubMedCrossRef
8.
go back to reference Bouza E, Rodríguez-Créixems M, Alcalá L, et al. Is Clostridium difficile infection an increasingly common severe disease in adult intensive care units? A 10-year experience. J Crit Care. 2015;30:543–9.PubMedCrossRef Bouza E, Rodríguez-Créixems M, Alcalá L, et al. Is Clostridium difficile infection an increasingly common severe disease in adult intensive care units? A 10-year experience. J Crit Care. 2015;30:543–9.PubMedCrossRef
9.
go back to reference Tschudin-Sutter S, Carroll KC, Tamma PD, et al. Impact of toxigenic clostridium difficile colonization on the risk of subsequent C. difficile infection in intensive care unit patients. Infect Control Hosp Epidemiol. 2015;36:1324–9.PubMedCrossRef Tschudin-Sutter S, Carroll KC, Tamma PD, et al. Impact of toxigenic clostridium difficile colonization on the risk of subsequent C. difficile infection in intensive care unit patients. Infect Control Hosp Epidemiol. 2015;36:1324–9.PubMedCrossRef
10.
go back to reference Sheth SG, LaMont JT. Gastrointestinal problems in the chronically critically ill patient. Clin Chest Med. 2001;22:135–47.PubMedCrossRef Sheth SG, LaMont JT. Gastrointestinal problems in the chronically critically ill patient. Clin Chest Med. 2001;22:135–47.PubMedCrossRef
12.
go back to reference Wanahita A, Goldsmith EA, Marino BJ, Musher DM. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med. 2003;115:543–6.PubMedCrossRef Wanahita A, Goldsmith EA, Marino BJ, Musher DM. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med. 2003;115:543–6.PubMedCrossRef
13.
go back to reference Jasiak NM, Alaniz C, Rao K, Veltman K, Nagel JL. Recurrent clostridium difficile infection in intensive care unit patients. Am J Infect Control. 2016;44:36–40.PubMedCrossRef Jasiak NM, Alaniz C, Rao K, Veltman K, Nagel JL. Recurrent clostridium difficile infection in intensive care unit patients. Am J Infect Control. 2016;44:36–40.PubMedCrossRef
14.
go back to reference Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–55.PubMedCrossRef Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–55.PubMedCrossRef
15.
go back to reference Rokas KEE, Johnson JW, Beardsley JR, Ohl CA, Luther VP, Williamson JC. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. Clin Infect Dis. 2015;61:934–41.PubMedCrossRef Rokas KEE, Johnson JW, Beardsley JR, Ohl CA, Luther VP, Williamson JC. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. Clin Infect Dis. 2015;61:934–41.PubMedCrossRef
16.
go back to reference Penziner S, Dubrovskaya Y, Press R, Safdar A. Fidaxomicin therapy in critically ill patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2015;59:1776–81.PubMedCrossRef Penziner S, Dubrovskaya Y, Press R, Safdar A. Fidaxomicin therapy in critically ill patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2015;59:1776–81.PubMedCrossRef
17.
go back to reference Tousseeva A, Jackson JD, Redell M, et al. Stability and recovery of DIFICID((R)) (Fidaxomicin) 200-mg crushed tablet preparations from three delivery vehicles, and administration of an aqueous dispersion via nasogastric tube. Drugs R D. 2014;14:309–14.PubMedPubMedCentralCrossRef Tousseeva A, Jackson JD, Redell M, et al. Stability and recovery of DIFICID((R)) (Fidaxomicin) 200-mg crushed tablet preparations from three delivery vehicles, and administration of an aqueous dispersion via nasogastric tube. Drugs R D. 2014;14:309–14.PubMedPubMedCentralCrossRef
18.
go back to reference Maseda E, Hernandez-Gancedo C, Lopez-Tofiño A, Suarez-de-la Rica A, Garcia-Bujalance S, Gilsanz F. Use of fidaxomicin through a nasogastric tube for the treatment of septic shock caused by Clostridium difficile infection in a patient with oral cancer admitted to the Surgical Critical Care Unit. Rev Esp Quimioter. 2013;26:375–7.PubMed Maseda E, Hernandez-Gancedo C, Lopez-Tofiño A, Suarez-de-la Rica A, Garcia-Bujalance S, Gilsanz F. Use of fidaxomicin through a nasogastric tube for the treatment of septic shock caused by Clostridium difficile infection in a patient with oral cancer admitted to the Surgical Critical Care Unit. Rev Esp Quimioter. 2013;26:375–7.PubMed
19.
go back to reference Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42:470–6.PubMedCrossRef Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42:470–6.PubMedCrossRef
20.
go back to reference Grundfest-Broniatowski S, Quader M, Alexander F, Walsh RM, Lavery I, Milsom J. Clostridium difficile colitis in the critically ill. Dis Colon Rectum. 1996;39:619–23.PubMedCrossRef Grundfest-Broniatowski S, Quader M, Alexander F, Walsh RM, Lavery I, Milsom J. Clostridium difficile colitis in the critically ill. Dis Colon Rectum. 1996;39:619–23.PubMedCrossRef
21.
go back to reference Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage. Ann Surg. 2011;254:423–9.PubMedCrossRef Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage. Ann Surg. 2011;254:423–9.PubMedCrossRef
22.
go back to reference Dela’O CM, Quyyum A, Dumire RD, Simunich TJ, Miller SL, Rodriguez A. Community hospital experience of refractory Clostridium difficile colitis: treatment and efficacy of diverting loop ileostomy and colonic lavage. Am Surg. 2014;80:E247–9.PubMed Dela’O CM, Quyyum A, Dumire RD, Simunich TJ, Miller SL, Rodriguez A. Community hospital experience of refractory Clostridium difficile colitis: treatment and efficacy of diverting loop ileostomy and colonic lavage. Am Surg. 2014;80:E247–9.PubMed
23.
go back to reference Lamontagne FO, Labb A-C, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg. 2007;245:267–72.PubMedPubMedCentralCrossRef Lamontagne FO, Labb A-C, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg. 2007;245:267–72.PubMedPubMedCentralCrossRef
24.
go back to reference Hautmann MG, Hipp M, Kölbl O. Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment? Radiat Oncol. 2011;6:89.PubMedPubMedCentralCrossRef Hautmann MG, Hipp M, Kölbl O. Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment? Radiat Oncol. 2011;6:89.PubMedPubMedCentralCrossRef
25.
go back to reference Rodríguez Garzotto A, Mérida García A, Muñoz Unceta N, et al. Risk factors associated with Clostridium difficile infection in adult oncology patients. Support Care Cancer. 2015;23:1569–77.PubMedCrossRef Rodríguez Garzotto A, Mérida García A, Muñoz Unceta N, et al. Risk factors associated with Clostridium difficile infection in adult oncology patients. Support Care Cancer. 2015;23:1569–77.PubMedCrossRef
26.
go back to reference Chopra T, Alangaden GJ, Chandrasekar P. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2010;8:1113–9.PubMedCrossRef Chopra T, Alangaden GJ, Chandrasekar P. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2010;8:1113–9.PubMedCrossRef
27.
go back to reference Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis. 1993;17:109–13.PubMedCrossRef Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis. 1993;17:109–13.PubMedCrossRef
28.
go back to reference Loo VG, Bourgault A-M, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365:1693–703.PubMedCrossRef Loo VG, Bourgault A-M, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365:1693–703.PubMedCrossRef
29.
go back to reference Bishop KD, Castillo JJ. Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk Lymphoma. 2012;53:1617–9.PubMedCrossRef Bishop KD, Castillo JJ. Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk Lymphoma. 2012;53:1617–9.PubMedCrossRef
30.
go back to reference Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol. 2013;31:2493–9.PubMedCrossRef Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol. 2013;31:2493–9.PubMedCrossRef
31.
go back to reference Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012;54:1053–63.PubMedPubMedCentralCrossRef Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012;54:1053–63.PubMedPubMedCentralCrossRef
32.
go back to reference Mani S, Rybicki L, Jagadeesh D, Mossad SB. Risk factors for recurrent Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplant 2016;1–5. Advance online publication, Jan 4, 2016. doi:10.1038/bmt.2015.311. Mani S, Rybicki L, Jagadeesh D, Mossad SB. Risk factors for recurrent Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplant 2016;1–5. Advance online publication, Jan 4, 2016. doi:10.​1038/​bmt.​2015.​311.
33.
go back to reference Nomura K, Fujimoto Y, Yamashita M, et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol. 2009;44:74–8.PubMedCrossRef Nomura K, Fujimoto Y, Yamashita M, et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol. 2009;44:74–8.PubMedCrossRef
34.
go back to reference Wang MS, Evans CT, Rodriguez T, Gerding DN, Johnson S. Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy. Infect Control Hosp Epidemiol. 2013;34:127–32.PubMedCrossRef Wang MS, Evans CT, Rodriguez T, Gerding DN, Johnson S. Clostridium difficile infection and limitations of markers for severity in patients with hematologic malignancy. Infect Control Hosp Epidemiol. 2013;34:127–32.PubMedCrossRef
35.
go back to reference Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med. 2015;175:1792–801.PubMedPubMedCentralCrossRef Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med. 2015;175:1792–801.PubMedPubMedCentralCrossRef
36.
go back to reference Parmar SR, Bhatt V, Yang J, Zhang Q, Schuster M. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. J Oncol Pharm Pract. 2014;20:172–82.PubMedCrossRef Parmar SR, Bhatt V, Yang J, Zhang Q, Schuster M. A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. J Oncol Pharm Pract. 2014;20:172–82.PubMedCrossRef
37.
go back to reference Donnelly JP, Wang HE, Locke JE, Mannon RB, Safford MM, Baddley JW. Hospital-onset Clostridium difficile infection among solid organ transplant recipients. Am J Transplant. 2015;15:2970–7.PubMedCrossRef Donnelly JP, Wang HE, Locke JE, Mannon RB, Safford MM, Baddley JW. Hospital-onset Clostridium difficile infection among solid organ transplant recipients. Am J Transplant. 2015;15:2970–7.PubMedCrossRef
38.
go back to reference Paudel S, Zacharioudakis IM, Zervou FN, Ziakas PD, Mylonakis E. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS ONE. 2015;10:e0124483–516.PubMedPubMedCentralCrossRef Paudel S, Zacharioudakis IM, Zervou FN, Ziakas PD, Mylonakis E. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS ONE. 2015;10:e0124483–516.PubMedPubMedCentralCrossRef
39.
go back to reference Angarone M, Ison MG. Diarrhea in solid organ transplant recipients. Curr Opin Infect Dis. 2015;28:308–16.PubMedCrossRef Angarone M, Ison MG. Diarrhea in solid organ transplant recipients. Curr Opin Infect Dis. 2015;28:308–16.PubMedCrossRef
40.
go back to reference Pant C, Deshpande A, Gilroy R, Olyaee M, Donskey CJ. Rising incidence of Clostridium difficile related discharges among hospitalized children in the United States. Infect Control Hosp Epidemiol. 2015;37:104–6.PubMedCrossRef Pant C, Deshpande A, Gilroy R, Olyaee M, Donskey CJ. Rising incidence of Clostridium difficile related discharges among hospitalized children in the United States. Infect Control Hosp Epidemiol. 2015;37:104–6.PubMedCrossRef
41.
go back to reference Mittal C, Hassan S, Arshad S, et al. Clostridium difficile infection in liver transplant recipients: a retrospective study of rates, risk factors and outcomes. Am J Transplant. 2014;14:1901–7.PubMedCrossRef Mittal C, Hassan S, Arshad S, et al. Clostridium difficile infection in liver transplant recipients: a retrospective study of rates, risk factors and outcomes. Am J Transplant. 2014;14:1901–7.PubMedCrossRef
42.
go back to reference Pant C, Anderson MP, O’Connor JA, Marshall CM, Deshpande A, Sferra TJ. Association of Clostridium difficile infection with outcomes of hospitalized solid organ transplant recipients: results from the 2009 Nationwide Inpatient Sample database. Transplant Infect Dis. 2012;14:540–7.CrossRef Pant C, Anderson MP, O’Connor JA, Marshall CM, Deshpande A, Sferra TJ. Association of Clostridium difficile infection with outcomes of hospitalized solid organ transplant recipients: results from the 2009 Nationwide Inpatient Sample database. Transplant Infect Dis. 2012;14:540–7.CrossRef
43.
go back to reference Dubberke ER, Burdette SD, the AST Infectious Diseases Community of Practice. Clostridium difficile infections in solid organ transplantation. Am J Transplant 2013; 13:42–49. Dubberke ER, Burdette SD, the AST Infectious Diseases Community of Practice. Clostridium difficile infections in solid organ transplantation. Am J Transplant 2013; 13:42–49.
44.
go back to reference Naderer OJ, Dupuis RE, Heinzen EL, Wiwattanawongsa K, Johnson MW, Smith PC. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol. 2005;45:219–26.PubMedCrossRef Naderer OJ, Dupuis RE, Heinzen EL, Wiwattanawongsa K, Johnson MW, Smith PC. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol. 2005;45:219–26.PubMedCrossRef
45.
go back to reference Hao C, Anwei M, Bing C, et al. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia. Liver Transplant. 2008;14:1165–73.CrossRef Hao C, Anwei M, Bing C, et al. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia. Liver Transplant. 2008;14:1165–73.CrossRef
46.
go back to reference Smith EP. Hematologic disorders after solid organ transplantation. Hematol Am Soc Hematol Educ Progr. 2010;2010:281–6. Smith EP. Hematologic disorders after solid organ transplantation. Hematol Am Soc Hematol Educ Progr. 2010;2010:281–6.
47.
go back to reference Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled Trials. Clin Infect Dis. 2012;55:S93–103.PubMedPubMedCentralCrossRef Crook DW, Walker AS, Kean Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled Trials. Clin Infect Dis. 2012;55:S93–103.PubMedPubMedCentralCrossRef
48.
go back to reference Clutter DS, Dubrovskaya Y, Merl MY, Teperman L, Press R, Safdar A. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother. 2013;57:4501–5.PubMedPubMedCentralCrossRef Clutter DS, Dubrovskaya Y, Merl MY, Teperman L, Press R, Safdar A. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother. 2013;57:4501–5.PubMedPubMedCentralCrossRef
49.
go back to reference Boutros M, Al-Shaibi M, Chan G, et al. Clostridium difficile colitis. Transplantation. 2012;93:1051–7.PubMedCrossRef Boutros M, Al-Shaibi M, Chan G, et al. Clostridium difficile colitis. Transplantation. 2012;93:1051–7.PubMedCrossRef
50.
go back to reference Friedman-Moraco RJ, Mehta AK, Lyon GM, Kraft CS. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transplant. 2014;14:477–80.PubMedPubMedCentralCrossRef Friedman-Moraco RJ, Mehta AK, Lyon GM, Kraft CS. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transplant. 2014;14:477–80.PubMedPubMedCentralCrossRef
51.
go back to reference Hsu JL, Enser JJ, McKown T, et al. Outcomes of Clostridium difficile infection in recipients of solid abdominal organ transplants. Clin Transplant. 2014;28:267–73.PubMedPubMedCentralCrossRef Hsu JL, Enser JJ, McKown T, et al. Outcomes of Clostridium difficile infection in recipients of solid abdominal organ transplants. Clin Transplant. 2014;28:267–73.PubMedPubMedCentralCrossRef
52.
go back to reference Gellad ZF, Alexander BD, Liu JK, et al. Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients. Transplant Infect Dis. 2007;9:276–80.CrossRef Gellad ZF, Alexander BD, Liu JK, et al. Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients. Transplant Infect Dis. 2007;9:276–80.CrossRef
53.
go back to reference Muñoz P, Giannella M, Alcalá L, et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer? J Heart Lung Transplant. 2007;26:907–14.PubMedCrossRef Muñoz P, Giannella M, Alcalá L, et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer? J Heart Lung Transplant. 2007;26:907–14.PubMedCrossRef
54.
go back to reference Monaghan TM, Cockayne A, Mahida YR. Pathogenesis of Clostridium difficile infection and Its potential role in inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1957–66.PubMedCrossRef Monaghan TM, Cockayne A, Mahida YR. Pathogenesis of Clostridium difficile infection and Its potential role in inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1957–66.PubMedCrossRef
55.
go back to reference Goodhand JR, Alazawi W, Rampton DS. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther. 2010;33:428–41.PubMedCrossRef Goodhand JR, Alazawi W, Rampton DS. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther. 2010;33:428–41.PubMedCrossRef
56.
57.
go back to reference Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol. 2009;104:1162–9.PubMedCrossRef Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol. 2009;104:1162–9.PubMedCrossRef
58.
go back to reference Ramos-Martínez A, Ortiz-Balbuena J, Curto-García I, et al. Risk factors for Clostridium difficile diarrhea in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2015;107:4–8.PubMed Ramos-Martínez A, Ortiz-Balbuena J, Curto-García I, et al. Risk factors for Clostridium difficile diarrhea in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2015;107:4–8.PubMed
59.
go back to reference Czepiel J, Biesiada G, Perucki W, Mach T. Clostridium difficile infection in patients with inflammatory bowel disease. Prz Gastroenterol. 2014;3:125–9. Czepiel J, Biesiada G, Perucki W, Mach T. Clostridium difficile infection in patients with inflammatory bowel disease. Prz Gastroenterol. 2014;3:125–9.
60.
go back to reference Killeen S, Martin ST, Hyland J, O’Connell PR, Winter DC. Clostridium difficile enteritis: a new role for an old foe. Surgeon. 2014;12:256–62.PubMedCrossRef Killeen S, Martin ST, Hyland J, O’Connell PR, Winter DC. Clostridium difficile enteritis: a new role for an old foe. Surgeon. 2014;12:256–62.PubMedCrossRef
61.
go back to reference Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30:253–64.PubMedCrossRef Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30:253–64.PubMedCrossRef
62.
go back to reference Regnault H, Bourrier A, Lalande V, et al. Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: a retrospective assessment. Digest Liver Dis. 2014;46:1086–92.CrossRef Regnault H, Bourrier A, Lalande V, et al. Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: a retrospective assessment. Digest Liver Dis. 2014;46:1086–92.CrossRef
63.
go back to reference Ananthakrishnan AN, Guzman-Perez R, Gainer V, et al. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:789–95.PubMedPubMedCentralCrossRef Ananthakrishnan AN, Guzman-Perez R, Gainer V, et al. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:789–95.PubMedPubMedCentralCrossRef
64.
go back to reference Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficile Infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339–44.PubMedCrossRef Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficile Infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339–44.PubMedCrossRef
65.
go back to reference Nitzan O. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment. World J Gastroeneterol. 2013;19:7577–85.CrossRef Nitzan O. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment. World J Gastroeneterol. 2013;19:7577–85.CrossRef
67.
go back to reference Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2016; (In press, available online Feb 22, 2016). Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2016; (In press, available online Feb 22, 2016).
68.
go back to reference Ben-Horin S, Margalit M, Bossuyt P, et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection. Clin Gastroenterol Hepatol. 2009;7:981–7.PubMedCrossRef Ben-Horin S, Margalit M, Bossuyt P, et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection. Clin Gastroenterol Hepatol. 2009;7:981–7.PubMedCrossRef
69.
go back to reference Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72.PubMedCrossRef Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72.PubMedCrossRef
70.
go back to reference Keddis MT, Khanna S, Noheria A, Baddour LM, Pardi DS, Qian Q. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc. 2012;87:1046–53.PubMedPubMedCentralCrossRef Keddis MT, Khanna S, Noheria A, Baddour LM, Pardi DS, Qian Q. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc. 2012;87:1046–53.PubMedPubMedCentralCrossRef
71.
go back to reference Phatharacharukul P, Thongprayoon C, Cheungpasitporn W, Edmonds PJ, Mahaparn P, Bruminhent J. The risks of incident and recurrent Clostridium difficile-associated diarrhea in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis. Dig Dis Sci. 2015;60:2913–22.PubMedCrossRef Phatharacharukul P, Thongprayoon C, Cheungpasitporn W, Edmonds PJ, Mahaparn P, Bruminhent J. The risks of incident and recurrent Clostridium difficile-associated diarrhea in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis. Dig Dis Sci. 2015;60:2913–22.PubMedCrossRef
72.
go back to reference Kim SC, Seo MY, Lee JY, et al. Advanced chronic kidney disease: a strong risk factor for Clostridium difficile infection. Korean J Intern Med. 2016;31:125–33.PubMedCrossRef Kim SC, Seo MY, Lee JY, et al. Advanced chronic kidney disease: a strong risk factor for Clostridium difficile infection. Korean J Intern Med. 2016;31:125–33.PubMedCrossRef
73.
go back to reference Pant C, Deshpande A, Anderson MP, Sferra TJ. Clostridium difficile infection is associated with poor outcomes in end-stage renal disease. J Investig Med. 2012;60:529–32.PubMedCrossRef Pant C, Deshpande A, Anderson MP, Sferra TJ. Clostridium difficile infection is associated with poor outcomes in end-stage renal disease. J Investig Med. 2012;60:529–32.PubMedCrossRef
74.
go back to reference Thongprayoon C, Cheungpasitporn W, Phatharacharukul P, Mahaparn P, Bruminhent J. High mortality risk in chronic kidney disease and end stage kidney disease patients with Clostridium difficile infection: a systematic review and meta-analysis. J Nat Sci 2015; 1. Available in PMC April 13, 2015. Thongprayoon C, Cheungpasitporn W, Phatharacharukul P, Mahaparn P, Bruminhent J. High mortality risk in chronic kidney disease and end stage kidney disease patients with Clostridium difficile infection: a systematic review and meta-analysis. J Nat Sci 2015; 1. Available in PMC April 13, 2015.
75.
go back to reference Kovithavongs T. Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant. 1999;14:2256–7.PubMedCrossRef Kovithavongs T. Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant. 1999;14:2256–7.PubMedCrossRef
76.
go back to reference Thongprayoon C, Cheungpasitporn W, Phatharacharukul P, et al. Chronic kidney disease and end-stage renal disease are risk factors for poor outcomes of Clostridium difficile infection: a systematic review and meta-analysis. Int J Clin Pract. 2015;69:998–1006.PubMedPubMedCentralCrossRef Thongprayoon C, Cheungpasitporn W, Phatharacharukul P, et al. Chronic kidney disease and end-stage renal disease are risk factors for poor outcomes of Clostridium difficile infection: a systematic review and meta-analysis. Int J Clin Pract. 2015;69:998–1006.PubMedPubMedCentralCrossRef
77.
go back to reference Do AN, Fridkin SK, Yechouron A, et al. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998;26:954–9.PubMedCrossRef Do AN, Fridkin SK, Yechouron A, et al. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998;26:954–9.PubMedCrossRef
78.
go back to reference Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 2009;136:1206–14.PubMedCrossRef Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 2009;136:1206–14.PubMedCrossRef
79.
go back to reference D’Agostino RB, Collins SH, Pencina KM, Kean Y, Gorbach S. Risk estimation for recurrent Clostridium difficile rnfection based on clinical factors. Clin Infect Dis. 2014;58:1386–93.PubMedCrossRef D’Agostino RB, Collins SH, Pencina KM, Kean Y, Gorbach S. Risk estimation for recurrent Clostridium difficile rnfection based on clinical factors. Clin Infect Dis. 2014;58:1386–93.PubMedCrossRef
80.
go back to reference Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59:345–54.PubMedCrossRef Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59:345–54.PubMedCrossRef
81.
go back to reference Rao S, Kupfer Y, Pagala M, Chapnick E, Tessler S. Systemic absorption of oral vancomycin in patients with Clostridium difficile infection. Scand J Infect Dis. 2011;43:386–8.PubMedCrossRef Rao S, Kupfer Y, Pagala M, Chapnick E, Tessler S. Systemic absorption of oral vancomycin in patients with Clostridium difficile infection. Scand J Infect Dis. 2011;43:386–8.PubMedCrossRef
82.
go back to reference Pogue JM, DePestel DD, Kaul DR, Khaled Y, Frame DG. Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract. Transplant Infect Dis. 2009;11:467–70.CrossRef Pogue JM, DePestel DD, Kaul DR, Khaled Y, Frame DG. Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract. Transplant Infect Dis. 2009;11:467–70.CrossRef
83.
go back to reference Pettit NN, DePestel DD, Fohl AL, Eyler R, Carver PL. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection. Pharmacotherapy. 2015;35:119–26.PubMedCrossRef Pettit NN, DePestel DD, Fohl AL, Eyler R, Carver PL. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection. Pharmacotherapy. 2015;35:119–26.PubMedCrossRef
84.
go back to reference Mullane KM, Cornely OA, Crook DW, et al. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol. 2013;38:1–11.PubMedCrossRef Mullane KM, Cornely OA, Crook DW, et al. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol. 2013;38:1–11.PubMedCrossRef
85.
go back to reference Rubio-Terres C, Cobo Reinoso J, Grau Cerrato S, et al. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain. Eur J Clin Microbiol Infect Dis. 2015;34:2213–23.PubMedCrossRef Rubio-Terres C, Cobo Reinoso J, Grau Cerrato S, et al. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain. Eur J Clin Microbiol Infect Dis. 2015;34:2213–23.PubMedCrossRef
86.
go back to reference Sears P, Crook DW, Louie TJ, Miller MA, Weiss K. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis. 2012;55(Suppl 2):S116–20.PubMedPubMedCentralCrossRef Sears P, Crook DW, Louie TJ, Miller MA, Weiss K. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis. 2012;55(Suppl 2):S116–20.PubMedPubMedCentralCrossRef
87.
go back to reference Tabaqchali S, O’Farrell S, Nash JQ, Wilks M. Vaginal carriage and neonatal acquisition of Clostridium difficile. J Med Microbiol. 1984;18:47–53.PubMedCrossRef Tabaqchali S, O’Farrell S, Nash JQ, Wilks M. Vaginal carriage and neonatal acquisition of Clostridium difficile. J Med Microbiol. 1984;18:47–53.PubMedCrossRef
88.
go back to reference Arsura EL, Fazio RA, Wickremesinghe PC. Pseudomembranous colitis following prophylactic antibiotic use in primary cesarean section. Am J Obstet Gynecol. 1985;151:87–9.PubMedCrossRef Arsura EL, Fazio RA, Wickremesinghe PC. Pseudomembranous colitis following prophylactic antibiotic use in primary cesarean section. Am J Obstet Gynecol. 1985;151:87–9.PubMedCrossRef
89.
go back to reference James AH, Katz VL, Dotters DJ, Rogers RG. Clostridium difficile infection in obstetric and gynecologic patients. South Med J. 1997;90:889–92.PubMedCrossRef James AH, Katz VL, Dotters DJ, Rogers RG. Clostridium difficile infection in obstetric and gynecologic patients. South Med J. 1997;90:889–92.PubMedCrossRef
90.
go back to reference Ghai S, Ghai V, Sunderji S. Fulminant postcesarean Clostridium difficile pseudomembranous colitis. Obstet Gynecol. 2007;109:541–3.PubMedCrossRef Ghai S, Ghai V, Sunderji S. Fulminant postcesarean Clostridium difficile pseudomembranous colitis. Obstet Gynecol. 2007;109:541–3.PubMedCrossRef
91.
go back to reference Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk-four states. Morb Mortal Wkly Rep. 2005;2005(54):1201–5. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk-four states. Morb Mortal Wkly Rep. 2005;2005(54):1201–5.
92.
go back to reference Rouphael NG, O’Donnell JA, Bhatnagar J, et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am J Obstet Gynecol. 2008;198(635):e1–6.PubMed Rouphael NG, O’Donnell JA, Bhatnagar J, et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am J Obstet Gynecol. 2008;198(635):e1–6.PubMed
93.
go back to reference Kuntz JL, Yang M, Cavanaugh J, Saftlas AF, Polgreen PM. Trends in Clostridium difficile infection among peripartum women. Infect Control Hosp Epidemiol. 2010;31:532–4.PubMedCrossRef Kuntz JL, Yang M, Cavanaugh J, Saftlas AF, Polgreen PM. Trends in Clostridium difficile infection among peripartum women. Infect Control Hosp Epidemiol. 2010;31:532–4.PubMedCrossRef
94.
go back to reference Unger JA, Whimbey E, Gravett MG, Eschenbach DA. The emergence of Clostridium difficile infection among peripartum women: a case-control study of a C. difficile outbreak on an obstetrical service. Infect Dis Obstet Gynecol. 2011;2011:267249–58.PubMedPubMedCentralCrossRef Unger JA, Whimbey E, Gravett MG, Eschenbach DA. The emergence of Clostridium difficile infection among peripartum women: a case-control study of a C. difficile outbreak on an obstetrical service. Infect Dis Obstet Gynecol. 2011;2011:267249–58.PubMedPubMedCentralCrossRef
95.
go back to reference Venugopal AA, Gerding DN, Johnson S. Clostridium difficile infection rates and spectrum of disease among peripartum women at one hospital from 2003 to 2007 with molecular typing analysis of recovered Clostridium difficile isolates. Am J Infecti Control. 2011;39:206–11.CrossRef Venugopal AA, Gerding DN, Johnson S. Clostridium difficile infection rates and spectrum of disease among peripartum women at one hospital from 2003 to 2007 with molecular typing analysis of recovered Clostridium difficile isolates. Am J Infecti Control. 2011;39:206–11.CrossRef
96.
go back to reference Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70:298–304.PubMedCrossRef Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70:298–304.PubMedCrossRef
97.
go back to reference Pant C, Deshpande A, Desai M, et al. Outcomes of Clostridium difficile infection in pediatric solid organ transplant recipients. Transpl Infect Dis. 2016;18:31–6.PubMedCrossRef Pant C, Deshpande A, Desai M, et al. Outcomes of Clostridium difficile infection in pediatric solid organ transplant recipients. Transpl Infect Dis. 2016;18:31–6.PubMedCrossRef
98.
go back to reference Gupta A, Pardi DS, Baddour LM, Khanna S. Outcomes in children with Clostridium difficile infection: results from a nationwide survey. Gastroenterol Rep (Oxf). 2016. doi:10.1093/gastro/gow007 Gupta A, Pardi DS, Baddour LM, Khanna S. Outcomes in children with Clostridium difficile infection: results from a nationwide survey. Gastroenterol Rep (Oxf). 2016. doi:10.​1093/​gastro/​gow007
99.
go back to reference McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World J Gastroenterol. 2016;22:3078–128.PubMedPubMedCentralCrossRef McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World J Gastroenterol. 2016;22:3078–128.PubMedPubMedCentralCrossRef
100.
go back to reference González-Del Vecchio M, Álvarez-Uria A, Marin M, et al. Clinical significance of Clostridium difficile in children less than 2 years old. Pediatr Infect Dis J. 2016; 35:281–285. González-Del Vecchio M, Álvarez-Uria A, Marin M, et al. Clinical significance of Clostridium difficile in children less than 2 years old. Pediatr Infect Dis J. 2016; 35:281–285.
101.
go back to reference Schutze GE, Willoughby RE. Committee on infectious diseases. Clostridium difficile infection in infants and children. Pediatrics. 2013;131:196–200.PubMedCrossRef Schutze GE, Willoughby RE. Committee on infectious diseases. Clostridium difficile infection in infants and children. Pediatrics. 2013;131:196–200.PubMedCrossRef
102.
go back to reference Antonara S, Leber AL. Diagnosis of Clostridium difficile infections in children. J Clin Microbiol 2016; JCM.03014–15–38. Antonara S, Leber AL. Diagnosis of Clostridium difficile infections in children. J Clin Microbiol 2016; JCM.03014–15–38.
103.
go back to reference Hourigan SK, Sears CL, Oliva-Hemker M. Clostridium difficile infection in pediatric Inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1020–5.PubMedCrossRef Hourigan SK, Sears CL, Oliva-Hemker M. Clostridium difficile infection in pediatric Inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1020–5.PubMedCrossRef
104.
go back to reference Boyle NM, Magaret A, Stednick Z, et al. Evaluating risk factors for clostridium difficile infection in adult and pediatric hematopoietic cell transplant recipients. Antimicrob Resist Infect Control 2015; 1–11. Boyle NM, Magaret A, Stednick Z, et al. Evaluating risk factors for clostridium difficile infection in adult and pediatric hematopoietic cell transplant recipients. Antimicrob Resist Infect Control 2015; 1–11.
105.
go back to reference Crews JD, Anderson LR, Waller DK, Swartz MD, DuPont HL, Starke JR. Risk factors for community-associated Clostridium difficile-associated diarrhea in children. Pediatr Infect Dis J. 2015;34:919–23.PubMedPubMedCentralCrossRef Crews JD, Anderson LR, Waller DK, Swartz MD, DuPont HL, Starke JR. Risk factors for community-associated Clostridium difficile-associated diarrhea in children. Pediatr Infect Dis J. 2015;34:919–23.PubMedPubMedCentralCrossRef
106.
go back to reference Hourigan SK, Oliva-Hemker M. Fecal microbiota transplantation in children: a brief review. Pediatr Res. 2016;80:2–6.PubMedCrossRef Hourigan SK, Oliva-Hemker M. Fecal microbiota transplantation in children: a brief review. Pediatr Res. 2016;80:2–6.PubMedCrossRef
107.
go back to reference Nicholson MR, Thomsen IP, Slaughter JC, Creech CB, Edwards KM. Novel risk factors for recurrent Clostridium difficile infection in children. J Pediatr Gastroenterol Nutr. 2015;60:18–22.PubMedPubMedCentralCrossRef Nicholson MR, Thomsen IP, Slaughter JC, Creech CB, Edwards KM. Novel risk factors for recurrent Clostridium difficile infection in children. J Pediatr Gastroenterol Nutr. 2015;60:18–22.PubMedPubMedCentralCrossRef
108.
go back to reference Na JY, Park JM, Lee KS, Kang JO, Oh SH, Kim YJ. Clinical characteristics of symptomatic Clostridium difficile infection in children: conditions as infection risks and whether probiotics is effective. Pediatr Gastroenterol Hepatol Nutr. 2014;17:232–8.PubMedPubMedCentralCrossRef Na JY, Park JM, Lee KS, Kang JO, Oh SH, Kim YJ. Clinical characteristics of symptomatic Clostridium difficile infection in children: conditions as infection risks and whether probiotics is effective. Pediatr Gastroenterol Hepatol Nutr. 2014;17:232–8.PubMedPubMedCentralCrossRef
109.
go back to reference Khanna S, Baddour LM, Huskins WC, et al. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis. 2013;56:1401–6.PubMedPubMedCentralCrossRef Khanna S, Baddour LM, Huskins WC, et al. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis. 2013;56:1401–6.PubMedPubMedCentralCrossRef
110.
go back to reference Pai S, Aliyu SH, Enoch DA, Karas JA. Five years experience of Clostridium difficile infection in children at a UK tertiary hospital: proposed criteria for diagnosis and management. PLoS ONE. 2012;7:e51728.PubMedPubMedCentralCrossRef Pai S, Aliyu SH, Enoch DA, Karas JA. Five years experience of Clostridium difficile infection in children at a UK tertiary hospital: proposed criteria for diagnosis and management. PLoS ONE. 2012;7:e51728.PubMedPubMedCentralCrossRef
111.
go back to reference Kim J, Shaklee JF, Smathers S, et al. Risk factors and outcomes associated with severe Clostridium difficile infection in children. Pediatr Infect Dis J. 2012;31:134–8.PubMedCrossRef Kim J, Shaklee JF, Smathers S, et al. Risk factors and outcomes associated with severe Clostridium difficile infection in children. Pediatr Infect Dis J. 2012;31:134–8.PubMedCrossRef
112.
go back to reference Kelsen JR, Kim J, Latta D, et al. Recurrence rate of Clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:50–5.PubMedCrossRef Kelsen JR, Kim J, Latta D, et al. Recurrence rate of Clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:50–5.PubMedCrossRef
Metadata
Title
Clostridium difficile Infection in Special High-Risk Populations
Authors
Alberto Cózar-Llistó
Antonio Ramos-Martinez
Javier Cobo
Publication date
01-09-2016
Publisher
Springer Healthcare
Published in
Infectious Diseases and Therapy / Issue 3/2016
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI
https://doi.org/10.1007/s40121-016-0124-z

Other articles of this Issue 3/2016

Infectious Diseases and Therapy 3/2016 Go to the issue